INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.23
-0.12 (-0.51%)
At close: 4:00PM EST

23.23 0.00 (0.00%)
After hours: 5:02PM EST

Stock chart is not supported by your current browser
Previous Close23.35
Open23.37
Bid22.87 x 800
Ask24.00 x 1300
Day's Range23.04 - 23.93
52 Week Range11.31 - 31.58
Volume776,168
Avg. Volume991,973
Market Cap1.791B
Beta (3Y Monthly)2.70
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire9 days ago

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., Jan. 7, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to three new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on January 2, 2019 to purchase an aggregate 5,500 shares of Insmed common stock at an exercise price of $13.97 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019
    PR Newswire12 days ago

    Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019

    BRIDGEWATER, N.J., Jan. 4, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the U.S. launch of ARIKAYCE® (amikacin liposome inhalation suspension), including preliminary unaudited net product sales for the fourth quarter of 2018, and shared the Company's strategic priorities for 2019. ARIKAYCE was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on September 28, 2018, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients who have limited or no alternative treatment options.

  • GlobeNewswirelast month

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to two new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company. In connection with the commencement of their employment, the employees received options on December 3, 2018 to purchase an aggregate 58,990 shares of Insmed common stock at an exercise price of $18.70 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

  • ACCESSWIRE2 months ago

    Healthcare Stocks with Turnaround Potential

    HENDERSON, NV / ACCESSWIRE / November 14, 2018 / After a tough year, the prospect that a split congress could be a good thing for healthcare stocks is causing some investors to look again at several smaller ...

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for Insmed, Service Corporation International, EPR Properties, Nielsen Holdings Plc, NiSource, and Criteo S.A — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Insmed Announces Changes to its Board of Directors

    Elizabeth McKee Anderson has been appointed to Insmed’s board of directors, succeeding Myrtle Potter, who has retired as a member of the board following four years of service to Insmed due to the demands of her current role as Vant Operating Chair for Roivant Pharma, a division of Roivant Sciences. “I am excited to join Insmed’s board and bring my extensive strategic marketing and market access experience to the Company as it executes the launch of ARIKAYCE® (amikacin liposome inhalation suspension) and pursues potential regulatory submissions in Europe and Japan,” said Anderson. Donald Hayden, Jr. has stepped down as chairman of the board after 13 years of distinguished service and will continue to serve as a director.

  • GlobeNewswire2 months ago

    Insmed to Present at Three November Conferences

    BRIDGEWATER, N.J., Nov. 06, 2018 -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare.

  • GlobeNewswire3 months ago

    Insmed Reports Third Quarter 2018 Financial Results and Provides Business Update

    —Quarter Highlighted by U.S. FDA Approval of ARIKAYCE® (amikacin liposome inhalation suspension), Followed by Immediate Launch— BRIDGEWATER, N.J., Oct. 30, 2018 -- Insmed.

  • GlobeNewswire3 months ago

    Insmed to Host Third Quarter 2018 Financial Results Conference Call on Tuesday, October 30, 2018

    Insmed Incorporated (INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its third quarter 2018 financial results on Tuesday, October 30, 2018. Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, October 30, 2018 to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 2556408.

  • ACCESSWIRE6 months ago

    Free Technical Research on Insmed and Three More Biotech Equities

    On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM).

  • ACCESSWIRE8 months ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Insmed

    NEW YORK, NY / ACCESSWIRE / May 25, 2018 / U.S. markets were weighed down by the energy sector on Thursday as U.S. crude oil prices closed lower for the third consecutive session. However, major indexes ...